Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-98,709
Closed -$3.1M 393
2025
Q2
$3.1M Sell
98,709
-7,630
-7% -$252K 0.01% 667
2025
Q1
$4.06M Buy
106,339
+13,430
+14% +$570K 0.01% 594
2024
Q4
$4.08M Buy
92,909
+62,784
+208% +$2.76M 0.01% 591
2024
Q3
$1.3M Buy
30,125
+9,327
+45% +$416K ﹤0.01% 833
2024
Q2
$940K Buy
20,798
+4,326
+26% +$225K ﹤0.01% 879
2024
Q1
$1.03M Buy
16,472
+3,897
+31% +$233K ﹤0.01% 840
2023
Q4
$704K Sell
12,575
-63,382
-83% -$3.16M ﹤0.01% 893
2023
Q3
$4.01M Buy
75,957
+3,557
+5% +$207K 0.01% 574
2023
Q2
$4.64M Sell
72,400
-1,500
-2% -$85.4K 0.02% 569
2023
Q1
$3.95M Hold
73,900
0.01% 620
2022
Q4
$3.96M Hold
73,900
0.01% 657
2022
Q3
$3.4M Buy
73,900
+3,067
+4% +$166K 0.01% 657
2022
Q2
$3.9M Buy
+70,833
New +$4.57M 0.01% 637
2022
Q1
Sell
-10,516
Closed -$832K 1199
2021
Q4
$832K Sell
10,516
-124,799
-92% -$10.4M ﹤0.01% 972
2021
Q3
$10.7M Sell
135,315
-2,905
-2% -$233K 0.03% 482
2021
Q2
$10.9M Sell
138,220
-35,325
-20% -$2.7M 0.03% 492
2021
Q1
$13.1M Sell
173,545
-11,271
-6% -$826K 0.04% 458
2020
Q4
$12.2M Hold
184,816
0.04% 457
2020
Q3
$9.98M Buy
184,816
+7,785
+4% +$428K 0.04% 457
2020
Q2
$8.5M Buy
+177,031
New +$7.82M 0.03% 473
2019
Q3
Sell
-13,479
Closed -$650K 1314
2019
Q2
$650K Buy
+13,479
New +$649K ﹤0.01% 1054

Other funds holding ENOV

Axa's ENOV Position: Q3 2025 in Review

Axa sold out of Enovis (ENOV) in Q3 2025, closing a stake of 98,709 shares — an estimated $3.1M sold.

Axa first reported a position in ENOV in Q2 2019 and held it in 21 quarters. The position peaked at $13.1M in Q1 2021. 278 funds tracked by Wall St. Rank hold ENOV as of Q3 2025.

  • Axa reported no remaining Enovis position as of Q3 2025 after selling out during the quarter.
  • Axa sold 98,709 Enovis shares in Q3 2025, an estimated $3.1M.
  • Axa first reported a position in Enovis in Q2 2019 and held it in 21 quarters.
  • Axa's Enovis position peaked at $13.1M in Q1 2021.
  • 278 funds tracked by Wall St. Rank held Enovis as of Q3 2025.

Based on Axa's 13F filing for Q3 2025, filed 14 Nov 2025.